The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase

In this study, we have focused on the European Union-approved antimalarial pyronaridine which was found to have in vitro activity against Mycobacterium tuberculosis (MIC 5  μg/mL). In macromolecular synthesis assays, pyronaridine resulted in a severe decrease in incorporation of 14C-uracil and 14C-leucine similar to the effect of rifampicin, a known inhibitor of M. tuberculosis RNA polymerase.

Source: Tuberculosis - August 11, 2018 Category: Respiratory Medicine Authors: Giorgia Mori, Beatrice Silvia Orena, Clara Franch, Lesley A. Mitchenall, Adwait Anand Godbole, Liliana Rodrigues, Clara Aguilar-P érez, Júlia Zemanová, Stanislav Huszár, Martin Forbak, Thomas R. Lane, Mohamad Sabbah, Nathalie Deboosere, Rosangela Frit Tags: Drug Discovery and Resistance Source Type: research